Targeting converging therapeutic pathways to overcome hypertension

International Journal of Cardiology

Volumn 132, Issue 3, 2009, Pages 297-299

  Koh, Kwang Kon ^a   Quon, Michael J ^b  

^a Gachon University College of Medicine   (South Korea)

^b National Institutes of Health   (United States)

Author keywords

Atherosclerosis; Blood pressure; Combination treatment; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; FENOFIBRATE; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RAMIPRIL; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMORBIDITY; ENDOTHELIUM, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; RISK FACTORS;

EID: 60649100201     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.150     Document Type: Editorial

References (11)

1. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation?. Circulation 92 (1995) 1079-1082
2. Tijssen J.G., and Hugenholtz P.G. Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur Heart J 17 (1996) 1152-1157
3. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 13 (2000) 3S-10S
4. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
5. Rodriguez-Porcel M., Lerman L.O., Herrmann J., Sawamura T., Napoli C., and Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol 23 (2003) 885-891
6. Kim J., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
7. Koh K.K., Han S.H., and Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46 (2005) 1978-1985
8. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45 (2005) 1088-1093
9. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
10. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic, hypertensive patients. Diabetes Care 29 (2006) 195-201
11. Han S.H., Quon M.J., Kim J., and Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 49 (2007) 531-538